Insight Molecular Diagnostics (IMDX) Gross Profit (2020 - 2026)

Insight Molecular Diagnostics has disclosed Gross Profit across 7 years of filings, most recently posting $15000.0 for Q1 2026.

• Gross Profit for Q1 2026 came in at $15000.0, down 98.87% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.0 million (down 50.5% YoY), and the FY2025 annual result was $2.3 million, up 210.54% from the prior year.
• Gross Profit came in at $15000.0 for Q1 2026 at Insight Molecular Diagnostics, down from $496000.0 in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $1.3 million in Q1 2025 to a low of -$269000.0 in Q3 2022.
• The 5-year median for Gross Profit is $50000.0 (2024), against an average of $203529.4.
• Across the five-year window, Gross Profit plunged 333.33% in 2023 and jumped 2844.44% in 2025, its largest moves.
• Insight Molecular Diagnostics' Gross Profit stood at -$27000.0 in 2022, then plunged by 333.33% to -$117000.0 in 2023, then surged by 608.55% to $595000.0 in 2024, then retreated by 16.64% to $496000.0 in 2025, then slumped by 96.98% to $15000.0 in 2026.
• The last three Gross Profit figures came in at $15000.0 (Q1 2026), $496000.0 (Q4 2025), and $139000.0 (Q3 2025), per Business Quant data.